Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Tenaya Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Tenaya Therapeutics, Inc.? What does TNYA stand for in stocks?
TNYA is the stock ticker symbol of Tenaya Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Tenaya Therapeutics, Inc. (TNYA)?
As of Tue Oct 29 2024, market cap of Tenaya Therapeutics, Inc. is 154.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of TNYA stock?
You can check TNYA's fair value in chart for subscribers.
Is Tenaya Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether TNYA is over valued or under valued. Whether Tenaya Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Tenaya Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNYA.